Hepatitis C Management in Special Populations
Summary
- The AASLD/IDSA (Management Guidelines)[AASLD-IDSA HCV] and EASL (Management Guidelines)[EASL HCV] guidance panels provide recommendations for the use of DAA regimens in the treatment of HCV infection in patients with decompensated cirrhosis: Table 11
- DAA regimens that include protease inhibitors should not be used
- Treatment with sofosbuvir in combination with NS5A inhibitors, with or without ribavirin, is recommended
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content